Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Ross Camidge, D.; Ryun Kim, Hye; Ahn, Myung‐Ju; Chih‐Hsin Yang, James; Han, Ji‐Youn; Seok Lee, Jong; J. Hochmair, Maximilian; Yu-Chung Li, Jacky; Chang, Gee‐Chen; Hyeong Lee, Ki; Gridelli, Cesare; Delmonte, Angelo; García Campelo, Rosario; Kim, Dong‐Wan; Bearz, Alessandra; Griesinger, Frank; Morabito, Alessandro; Felip, Enriqueta; Califano, Raffaele; Ghosh, Sharmistha; I. Spira, Alexander; Gettinger, Scott; Tiseo, Marcello; Gupta, Neeraj; Haney, J.; Kerstein, David; Popat, Sanjay

doi:10.1056/nejmoa1810171

Public

Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Sep 25, 2018

Authors:

D. Ross Camidge

Hye Ryun Kim

Myung‐Ju Ahn

Abstract

BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive...

Subject

Crizotinib

Lung cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!